BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 38848146)

  • 1. Overexpression of zinc finger DHHC-type containing 1 is associated with poor prognosis and cancer cell growth and metastasis in uterine corpus endometrial carcinoma.
    Jiang N; Li D; Han Y; Luo ZG; Liu LB
    Aging (Albany NY); 2024 Jun; 16(11):9784-9812. PubMed ID: 38848146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and Clinical Validation of Novel 8-Gene Prognostic Signature Associated With the Proportion of Regulatory T Cells by Weighted Gene Co-Expression Network Analysis in Uterine Corpus Endometrial Carcinoma.
    Liu J; Geng R; Yang S; Shao F; Zhong Z; Yang M; Ni S; Cai L; Bai J
    Front Immunol; 2021; 12():788431. PubMed ID: 34970268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. KDM4B, a potential prognostic biomarker revealed by large-scale public databases and clinical samples in uterine corpus endometrial carcinoma.
    Zhang M; Liu Y; Hou S; Wang Y; Wang C; Yin Y; Chen X
    Mol Omics; 2022 Jul; 18(6):506-519. PubMed ID: 35485290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pan-Cancer Gene Analysis of m6A Modification and Immune Infiltration in Uterine Corpus Endometrial Carcinoma.
    Xie BF; Xia Y; Lin DH; Lian B; Zhang ML; Liu L; Qin CR
    Comput Intell Neurosci; 2022; 2022():6530884. PubMed ID: 36199963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a necroptosis-related prognostic model for uterine corpus endometrial carcinoma.
    Zhang Q; Luo Y; Zhang S; Huang Q; Liu G
    Sci Rep; 2024 Feb; 14(1):4257. PubMed ID: 38383747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ALDH2 promotes uterine corpus endometrial carcinoma proliferation and construction of clinical survival prognostic model.
    Cui YQ; Xiang Y; Meng F; Ji CH; Xiao R; Li JP; Dai ZT; Liao XH
    Aging (Albany NY); 2021 Oct; 13(20):23588-23602. PubMed ID: 34670872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of an eight-m6A RNA methylation regulator prognostic signature of uterine corpus endometrial carcinoma based on bioinformatics analysis.
    Miao C; Fang X; Chen Y; Zhao Y; Guo Q
    Medicine (Baltimore); 2021 Dec; 100(49):e27689. PubMed ID: 34889221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Construction of N-7 methylguanine-related mRNA prognostic model in uterine corpus endometrial carcinoma based on multi-omics data and immune-related analysis.
    Zhao J; Zou J; Jiao W; Lin L; Wang J; Lin Z
    Sci Rep; 2022 Nov; 12(1):18813. PubMed ID: 36335189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive Analysis of ESRRA in Endometrial Cancer.
    Wang S; Huo X
    Technol Cancer Res Treat; 2021; 20():1533033821992083. PubMed ID: 33525981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LHX1 as a potential biomarker regulates EMT induction and cellular behaviors in uterine corpus endometrial carcinoma.
    Tian Y; Wen F; Wang S; Lv N
    Clinics (Sao Paulo); 2022; 77():100103. PubMed ID: 36116266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A 7-lncRNA signature predict prognosis of Uterine corpus endometrial carcinoma.
    Ouyang D; Li R; Li Y; Zhu X
    J Cell Biochem; 2019 Oct; 120(10):18465-18477. PubMed ID: 31168849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of Five m6A-Related lncRNA Genes as Prognostic Markers for Endometrial Cancer Based on TCGA Database.
    Shan L; Lu Y; Xiang CC; Zhu X; Zuo ED; Cheng X
    J Immunol Res; 2022; 2022():2547029. PubMed ID: 35571565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ZNF554 Inhibits Endometrial Cancer Progression via Regulating RBM5 and Inactivating WNT/β-Catenin Signaling Pathway.
    Zhu CC; Sun HL; Long TF; Lyu YY; Liu JL; Ni GT
    Curr Med Sci; 2024 Apr; 44(2):406-418. PubMed ID: 38619681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identifying immune subtypes of uterine corpus endometrial carcinoma and a four-paired-lncRNA signature with immune-related lncRNAs.
    Li N; Yu K; Lin Z; Zeng D
    Exp Biol Med (Maywood); 2022 Feb; 247(3):221-236. PubMed ID: 34704492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinicopathological role of Cyclin A2 in uterine corpus endometrial carcinoma: Integration of tissue microarrays and ScRNA-Seq.
    Mo WJ; Liang ZQ; Huang JZ; Huang ZG; Zhi ZF; Chen JH; Chen G; Zeng JJ; Feng ZB
    Int J Biol Markers; 2024 Jun; 39(2):168-183. PubMed ID: 38646803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High expression of the ferroptosis-associated MGST1 gene in relation to poor outcome and maladjusted immune cell infiltration in uterine corpus endometrial carcinoma.
    Yan J; Ye G; Shao Y
    J Clin Lab Anal; 2022 Apr; 36(4):e24317. PubMed ID: 35218676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of an Immune-Related LncRNA Prognostic Signature in Uterine Corpus Endometrial Carcinoma Patients.
    Sun XX; Wen HQ; Zhan BX; Yang P
    Clin Lab; 2021 Nov; 67(11):. PubMed ID: 34758230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification and validation of oxeiptosis-associated lncRNAs and prognosis-related signature genes to predict the immune status in uterine corpus endometrial carcinoma.
    Niu L; Wu Z
    Aging (Albany NY); 2023 May; 15(10):4236-4252. PubMed ID: 37211398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MMP11 and MMP17 are potential biomarkers for uterine corpus endometrial carcinoma prognosis.
    Zhang Y; Wang J; Fan Y; Lang F; Fu F; Liu Q
    Clin Transl Oncol; 2024 Mar; 26(3):653-663. PubMed ID: 37523078
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between Prognosis, Immune Infiltration Level, and Differential Expression of PARVG Gene in Uterine Corpus Endometrial Carcinoma.
    Wang F; Bi J; Yi C; Zhang Y; Zhang Y; Yue Q
    Contrast Media Mol Imaging; 2022; 2022():7376588. PubMed ID: 35655721
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.